Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exoRBD
- Development stage
- Preclinical
- Lead developer
- Codiak BioSciences
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
**exoRBD** is an engineered exosome-based therapeutic candidate developed by Codiak BioSciences as a pan-beta-coronavirus vaccine. It displays the receptor-binding domain (RBD) of SARS-CoV-2 on the surface of exosomes, leveraging exosome biology for targeted antigen presentation and immune stimulation to elicit broad protective immunity. Preclinical data demonstrate its ability to generate neutralizing antibodies and T-cell responses against multiple SARS-CoV-2 Variants of Concern (VoCs) as well as seven related sarbecoviruses, positioning it as a potential broad-spectrum prophylactic against emerging coronaviruses.
Beyond the preview
Go deeper on exoRBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exoRBD.